Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Background/Introduction: Lower-risk (IPSS low risk and Int-1) myelodysplastic syndromes (MDS) are typically treated supportively to address cytopenias. DNA methyltransferase inhibitors (DNMTi) such as azacitidine and decitabine (DEC) are FDA-approved for higher risk MDS patients (pts), and while the...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Manero, Guillermo, McCloskey, James K, Griffiths, Elizabeth A., Yee, Karen, Zeidan, Amer M., Al-Kali, Aref, Deeg, H. Joachim, Patel, Prapti, Sabloff, Mitchell, Keating, Mary-Margaret, Dao, Kim-Hien, Zhu, Nancy, Gabrail, Nashat Y., Fazal, Salman, Maly, Joseph, Odenike, Olatoyosi, Kantarjian, Hagop, DeZern, Amy E., O'Connell, Casey L., Roboz, Gail J., Busque, Lambert, Wells, Richard A., Amin, Harshad, Randhawa, Jasleen K., Leber, Brian, Hao, Yong, Keer, Harold N., Azab, Mohammad, Savona, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
637.Myelodysplastic Syndromes - Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701611/
http://dx.doi.org/10.1182/blood-2021-144648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701611/
http://dx.doi.org/10.1182/blood-2021-144648

Ejemplares similares